Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lot Consistency of RSVpreF in Healthy Adults
NCT05096208Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Started Oct 2021; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05096208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05096208.